A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorShanghai Pulmonary Hospital, Shanghai, China
About this trial
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
Eligibility criteria
Qualifiers
RR-TB/MDR-TB (resistant to at least isoniazid and rifampicin).
Poor efficacy of the original treatment regimen or no response to treatment or less than 4 effective drugs.
Disqualifiers
Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc.
Test confirms poor response to ZOL and IL-2 stimulation.
Trial design
Treatments tested in this trial
- Vγ2Vδ2 T lymphocyte-based immunotherapy
- Treatment regimens for MDR-TB
Treatment groups
30 Participants
are divided into 2 treatment groupsLocations
2Shanghai Pulmonary Hospital Shanghai China
Shanghai Pulmonary Hospital, Shanghai, China200433, Shanghai China
Sponsors and collaborators
Shanghai Pulmonary Hospital, Shanghai, China
Lead sponsor
Shanghai Public Health Clinical Center
Collaborator
Huashan Hospital
Collaborator
No.85 Hospital, Changning, Shanghai, China
Collaborator
Source ClinicalTrials.gov